

## SECTION 1 General principles

### 1 What is pharmacology? 1

- What is a drug? 1
- Origins and antecedents 1
- Pharmacology in the 20th and 21st centuries 2
  - Alternative therapeutic principles 3
  - The emergence of biotechnology 4
  - Pharmacology today 4

### 2 How drugs act: general principles 6

- Introduction 6
- Protein targets for drug binding 6
  - Drug receptors 6
  - Drug specificity 7
  - Receptor classification 8
  - Drug-receptor interactions 8
  - Competitive antagonism 11
  - Partial agonists and the concept of efficacy 12
  - Constitutive receptor activation and inverse agonists 14
  - Biased agonism 16
  - Allosteric modulation 17
  - Other forms of drug antagonism 17
- Desensitisation and tolerance 19
  - Change in receptors 19
  - Translocation of receptors 19
  - Exhaustion of mediators 20
  - Altered drug metabolism 20
  - Physiological adaptation 20
- Quantitative aspects of drug-receptor interactions 20
  - The binding reaction 20
  - Binding when more than one drug is present 21
- The nature of drug effects 22

### 3 How drugs act: molecular aspects 24

- Protein targets for drug action 24
  - Receptors 24
  - Ion channels 24
  - Enzymes 25
  - Transporters 25
- Receptor proteins 26
  - Types of receptor 26
  - Molecular structure of receptors 26
  - Type 1: ligand-gated ion channels 28
  - Type 2: G protein-coupled receptors 30
  - Type 3: kinase-linked and related receptors 42
  - Type 4: nuclear receptors 44
- Ion channels as drug targets 47
  - Ion selectivity 49
  - Gating 49
  - Molecular architecture of ion channels 49
  - Pharmacology of ion channels 50

- Control of receptor expression 51
- Receptors and disease 51

### 4 How drugs act: cellular aspects – excitation, contraction and secretion 54

- Regulation of intracellular calcium 54
  - Calcium entry mechanisms 54
  - Calcium extrusion mechanisms 57
  - Calcium release mechanisms 57
  - Calmodulin 58
- Excitation 58
  - The 'resting' cell 59
  - Electrical and ionic events underlying the action potential 59
  - Channel function 60
- Muscle contraction 65
  - Skeletal muscle 65
  - Cardiac muscle 65
  - Smooth muscle 65
- Release of chemical mediators 67
  - Exocytosis 68
  - Non-vesicular release mechanisms 69
- Epithelial ion transport 69

### 5 How drugs act: biopharmaceuticals and gene therapy 72

- Introduction 72
- Protein and peptide biopharmaceuticals 72
  - Monoclonal antibodies 74
  - Pharmacology of protein biopharmaceuticals 75
- Oligonucleotides 77
  - RNA drugs that target proteins 77
  - RNA drugs that target other nucleotides 79
  - RNA drugs that are used to encode proteins 79
  - Miscellaneous other RNA species with pharmacological potential 80
  - Problems with RNA biopharmaceuticals 80
- Gene therapy 81
  - Gene delivery 82
  - Controlling gene expression 84
- Safety and societal issues 84
- Therapeutic applications 85
- Future directions 85

### 6 Cell proliferation, apoptosis, repair and regeneration 87

- Cell proliferation 87
  - The cell cycle 87
  - Interactions between cells, growth factors and the extracellular matrix 90
- Angiogenesis 91
- Apoptosis and cell removal 91
  - Morphological changes in apoptosis 92
  - The major players in apoptosis 92
  - Pathways to apoptosis 92

**Pathophysiological implications 94**

- Repair and healing 94
- Hyperplasia 95
- The growth, invasion and metastasis of tumours 95
- Stem cells and regeneration 95

**Therapeutic prospects 95**

- Apoptotic mechanisms 96
- Angiogenesis and metalloproteinases 96
- Cell cycle regulation 96

**7 Cellular mechanisms: host defence 98****Introduction 98****The innate immune response 98**

- Pattern recognition 99

**The adaptive immune response 104**

- The induction phase 105
- The effector phase 106

**Systemic responses in inflammation 109**

- The role of the nervous system in inflammation 109
- Unwanted inflammatory and immune responses and their unintended consequences 109
- The outcome of the inflammatory response 110

**8 Method and measurement in pharmacology 112****Bioassay 112**

- Biological test systems 112
- General principles of bioassay 114

**Animal models of disease 116**

- Pharmacological models 116
- Genetically altered animal models 116
- Reducing use of animals in research 117

**Pharmacological studies in humans 118****Clinical trials 118**

- Risk of bias in randomised controlled trials 119
- The size of the sample 120
- Clinical outcome measures 120
- Placebos 120
- Meta-analysis 121
- Clinical consideration of benefit and risk 121

**9 Absorption and distribution of drugs 123****Introduction 123****Physical processes underlying drug disposition 123**

- The movement of drug molecules across cell barriers 123

- Binding of drugs to plasma proteins 129

- Partition into body fat and other tissues 130

**Drug absorption and routes of administration 130**

- Oral administration 131
- Oromucosal (sublingual or buccal) administration 133
- Rectal administration 133
- Application to epithelial surfaces 133
- Intravitreal injection 134

**Distribution of drugs in the body 135**

- Body fluid compartments 135
- Volume of distribution 136
- Drug interactions caused by altered absorption 137

- Drug interactions caused by altered distribution 137

**Special drug delivery systems 137****10 Drug metabolism and elimination 140****Introduction 140**

- Drug metabolism 140
- Phase 1 reactions 140
- Phase 2 reactions 142
- Stereoselectivity 142
- Inhibition of P450 143
- Induction of microsomal enzymes 143
- Presystemic ('first-pass') metabolism 143
- Pharmacologically active drug metabolites 144
- Drug interactions due to enzyme induction or inhibition 144

**Drug and metabolite excretion 146**

- Biliary excretion and enterohepatic circulation 146
- Renal excretion of drugs and metabolites 146
- Drug interactions due to altered drug excretion 148

**11 Pharmacokinetics 150****Introduction: definition and uses of pharmacokinetics 150**

- Uses of pharmacokinetics 151
- Scope of this chapter 151

**Drug elimination expressed as clearance 151****Single-compartment model 153**

- Repeated dosing 154
- Effect of variation in rate of absorption 154

**More complicated kinetic models 155**

- Two-compartment model 156
- Saturation kinetics 157

**Population pharmacokinetics 157****Limitations of pharmacokinetics 158****12 Individual variation, pharmacogenomics and personalised medicine 160****Introduction 160****Epidemiological factors and inter-individual variation of drug response 161**

- Ethnicity 161
- Age 161
- Pregnancy 162
- Disease 162
- Drug interactions 163

**Genetic variation in drug responsiveness 164**

- Single-gene pharmacokinetic disorders 165

**Therapeutic drugs and clinically available pharmacogenomic tests 166**

- Incorporating pharmacogenetic data into daily clinical workflows 167

**Conclusions 168**

## SECTION 2 Chemical mediators

### 13 Chemical mediators and the autonomic nervous system 170

Historical aspects 170

The autonomic nervous system 171

Basic anatomy and physiology 171

Transmitters in the autonomic nervous system 174

Some general principles of chemical transmission 174

Presynaptic modulation 174

Postsynaptic modulation 176

Transmitters other than acetylcholine and noradrenaline 177

Co-transmission 177

Termination of transmitter action 177

Denervation supersensitivity 179

Basic steps in neurochemical transmission: sites of drug action 180

### 14 Cholinergic transmission 182

Muscarinic and nicotinic actions of acetylcholine 182

Acetylcholine receptors 182

Nicotinic receptors 182

Muscarinic receptors 183

Physiology of cholinergic transmission 185

Acetylcholine synthesis and release 185

Electrical events in transmission at fast cholinergic synapses 186

Effects of drugs on cholinergic transmission 188

Drugs affecting muscarinic receptors 189

Drugs affecting autonomic ganglia 192

Drugs that act presynaptically 198

Drugs that enhance cholinergic transmission 198

Other drugs that enhance cholinergic transmission 203

### 15 Noradrenergic transmission 205

Catecholamines 205

Classification of adrenoceptors 205

Physiology of noradrenergic transmission 208

The noradrenergic neuron 208

Uptake and degradation of catecholamines 210

Drugs acting on noradrenergic transmission 210

Drugs acting on adrenoceptors 211

Drugs that affect noradrenergic neurons 221

### 16 5-Hydroxytryptamine and the purines 225

5-Hydroxytryptamine 225

Distribution, biosynthesis and degradation 225

Pharmacological effects 228

Drugs acting at 5-HT receptors 229

Clinical conditions in which 5-HT plays a role 231

Serotonin and carcinoid syndrome 231

Pulmonary hypertension 231

Purines 231

Purinergic receptors 232

The purinergic system in health and disease 234

The cardiovascular system 234

Asthma and inflammation 234

Platelets 235

Purines as neurotransmitters 235

Summary 235

### 17 Local hormones: histamine, lipids, peptides and proteins 237

Introduction 237

What is a 'mediator'? 237

Histamine 238

Synthesis and storage of histamine 238

Histamine release 238

Histamine receptors 238

Histamine actions 238

Eicosanoids 240

General remarks 240

Structure and biosynthesis 240

Prostanoids 242

Leukotrienes 245

Leukotriene receptors 245

Leukotriene actions 246

Other important fatty acid derivatives 247

Platelet-activating factor 248

Biosynthesis 248

Actions and role in inflammation 248

Sphingosine 1-phosphate 248

Biosynthesis and metabolism 248

Receptors and actions 249

Protein and peptide mediators 250

General principles 250

Types of protein and peptide mediator 250

Biosynthesis and regulation of peptides 250

Peptide precursors 251

Diversity within peptide families 252

Peptide trafficking and secretion 252

Bradykinin 252

Source and formation of bradykinin 252

Metabolism and inactivation of bradykinin 253

Bradykinin receptors 253

Actions and role in inflammation 253

Neuropeptides 254

Cytokines 254

Interleukins and related compounds 255

Chemokines 255

Interferons 257

The 'cytokine storm' 257

Proteins and peptides that down-regulate inflammation 257

Concluding remarks 258

### 18 Cannabinoids 260

Plant-derived cannabinoids ('phytocannabinoids') and their pharmacological effects 260

Pharmacological effects 260

Pharmacokinetic aspects 261

Adverse effects 261

Tolerance and dependence 261

Cannabinoid receptors 261

Endocannabinoids 263

Biosynthesis of endocannabinoids 263

- Termination of the endocannabinoid signal 263
- Physiological mechanisms 264
- Pathological involvement 264
- Synthetic cannabinoids 265
- Clinical applications 265

## 19 Nitric oxide and related mediators 267

- Introduction 267
- Biosynthesis of nitric oxide and its control 267
- Degradation and carriage of nitric oxide 269
- Effects of nitric oxide 270
  - Biochemical and cellular aspects 270
  - Vascular effects 271
  - Neuronal effects 271
  - Host defence 271
- Therapeutic aspects 271
  - Nitric oxide 271
  - Nitric oxide donors/precursors 271
  - Inhibition of nitric oxide synthesis 272
  - Nitric oxide replacement or potentiation 272
- Clinical conditions in which nitric oxide may play a part 272
- Related mediators 273

## SECTION 3 Drugs affecting major organ systems

### 20 The heart 275

- Introduction 275
- Physiology of cardiac function 275
  - Cardiac rate and rhythm 275
  - Cardiac contraction 279
  - Myocardial oxygen consumption and coronary blood flow 280
- Autonomic control of the heart 281
  - Sympathetic system 281
  - Parasympathetic system 282
- Cardiac natriuretic peptides 283
- Ischaemic heart disease 283
  - Angina 283
  - Acute coronary syndrome 283
- Drugs that affect cardiac function 284
  - Antidysrhythmic drugs 284
  - Drugs that act on myocardial contraction 287
  - Anti-anginal drugs 289

### 21 The vascular system 294

- Introduction 294
- Vascular structure and function 294
- Control of vascular smooth muscle tone 295
  - The vascular endothelium 295
  - The renin-angiotensin system 298
- Vasoactive drugs 299
  - Vasoconstrictor drugs 299
  - Vasodilator drugs 300
- Clinical uses of vasoactive drugs 305
  - Systemic hypertension 305
  - Heart failure 307
  - Vasodilatory shock and hypotensive states 309

- Peripheral vascular disease 310
- Raynaud's disease 310
- Pulmonary hypertension 310

### 22 Atherosclerosis and lipoprotein metabolism 313

- Introduction 313
- Atherogenesis 313
- Lipoprotein transport 314
  - Dyslipidaemia 315
- Prevention of atheromatous disease 316
- Lipid-lowering drugs 316
  - Statins: HMG-CoA reductase inhibitors 317
  - Bempedoic acid 318
  - Inhibition of PCSK9 318
  - Fibrates 319
  - Drugs that inhibit cholesterol absorption 319
  - Microsomal triglyceride transport protein (MTP) inhibitors 320
- Antisense oligonucleotides 320

### 23 Haemostasis and thrombosis 322

- Introduction 322
- Blood coagulation 322
  - Coagulation cascade 322
  - Vascular endothelium in haemostasis and thrombosis 324
- Drugs that act on the coagulation cascade 325
  - Coagulation defects 325
  - Thrombosis 326
- Platelet adhesion and activation 330
- Antiplatelet drugs 332
- Fibrinolysis (thrombolysis) 334
  - Fibrinolytic drugs 334

### 24 Haematopoietic system and treatment of anaemia 337

- Introduction 337
- The haematopoietic system 337
- Types of anaemia 339
- Haematinic agents 339
  - Iron 339
  - Folic acid and vitamin B<sub>12</sub> 342
- Haematopoietic growth factors 343
- Haemolytic anaemia 347
  - Drugs used to treat haemolytic anaemias 347

### 25 Anti-inflammatory and immunosuppressant drugs 350

- Introduction 350
- Cyclo-oxygenase inhibitors 350
  - Mechanism of action 351
  - Pharmacological actions 352
  - Some important NSAIDs and COXIBs 356
- Antirheumatoid drugs 359
  - Disease-modifying antirheumatic drugs 359
  - Immunosuppressant drugs 361
- Biologic disease-modifying antirheumatic drugs, anticytokine drugs and other biopharmaceuticals 364
- Drugs used in gout 365
- Antagonists of histamine 367

Possible future developments in anti-inflammatory therapy 369

## 26 Skin 371

- Introduction 371
- Structure of skin 371
- Common diseases of the skin 374
  - Acne 374
  - Rosacea 374
  - Baldness and hirsutism 376
  - Eczema 376
  - Pruritus 376
  - Urticaria 376
  - Psoriasis 377
  - Warts 377
  - Other infections 377
  - Melanoma 377
- Drugs acting on skin 377
  - Formulation 377
- Principal drugs used in skin disorders 378
  - Antimicrobial agents 378
  - Biopharmaceuticals 378
  - Glucocorticoids and other anti-inflammatory agents 379
  - Drugs used to control hair growth 380
  - Retinoids 380
  - Vitamin D analogues 381
- Agents acting by other mechanisms 381
- Concluding remarks 382

## 27 The eye 384

- Introduction 384
- Special pharmacokinetic considerations in the eye 384
  - Autonomic control of the lens and pupil, and related therapeutic drugs 385
- Treatment of inflammation and infection in the eye 386
- Control of intraocular pressure and treatment of glaucoma 387
  - Prostaglandin FP receptor agonists 387
  - $\beta_1$  adrenoceptor antagonists 387
  - $\alpha_2$  adrenoceptor agonists 387
  - Carbonic anhydrase inhibitors 387
  - Inhibitors of rho kinase 388
  - Muscarinic agonists 388
- Ocular vasculature and vascular endothelial growth factor inhibitors 388

## 28 Respiratory system 390

- The physiology of respiration 390
  - Control of breathing 390
  - Regulation of musculature, blood vessels and glands of the airways 390
- Pulmonary disease and its treatment 391
  - Bronchial asthma 391
  - Drugs used to treat and prevent asthma 393
  - Severe acute asthma (status asthmaticus) 398
  - Allergic emergencies 398
  - Chronic obstructive pulmonary disease 398
  - Bronchiectasis 399

Idiopathic pulmonary fibrosis 399  
Surfactants 400  
Cough 400

## 29 The kidney and urinary system 402

- Introduction 402
- Outline of renal function 402
- The structure and function of the nephron 402
  - Tubular function 404
  - Acid-base balance 407
  - Potassium balance 408
  - Excretion of organic molecules 408
  - Natriuretic peptides 408
  - Prostaglandins and renal function 409
- Drugs acting on the kidney 409
  - Diuretics 409
- Drugs that alter the pH of the urine 413
- Drugs that alter the excretion of organic molecules 413
- Drugs used in renal failure 414
  - Hyperphosphataemia 414
  - Hyperkalaemia 414
- Drugs used in urinary tract disorders 414

## 30 The gastrointestinal tract 416

- The innervation and hormones of the gastrointestinal tract 416
  - Neuronal control 416
  - Hormonal control 416
- Gastric secretion 416
  - The regulation of acid secretion by parietal cells 416
  - The coordination of factors regulating acid secretion 418
  - Drugs used to inhibit or neutralise gastric acid secretion 418
  - Treatment of *Helicobacter pylori* infection 420
  - Drugs that protect the mucosa 421
- Vomiting 421
  - The reflex mechanism of vomiting 421
  - Antiemetic drugs 423
- The motility of the GI tract 424
  - Purgatives 425
  - Drugs that increase gastrointestinal motility 425
  - Antidiarrhoeal agents 426
- Drugs for chronic bowel disease 427
- Drugs affecting the biliary system 428
- Future directions 428

## 31 The control of blood glucose and drug treatment of diabetes mellitus 429

- Introduction 429
- Control of blood glucose 429
- Pancreatic islet hormones 430
  - Insulin 431
  - Glucagon 433
  - Somatostatin 434
  - Amylin (islet amyloid polypeptide) 434
  - Incretins 434

- Diabetes mellitus 434
  - Drugs used in the treatment of diabetes 435
  - Treatment of diabetes mellitus 440

## 32 Obesity 443

- Introduction 443
  - Definition of obesity 443
- Obesity as a health problem 443
- Homeostatic mechanisms controlling energy balance 444
  - The role of peripheral signalling in body weight regulation 444
  - Neurological circuits that control body weight and eating behaviour 445
- The pathophysiology of human obesity 447
  - Food intake and obesity 448
  - Physical exercise and obesity 448
  - Genetic factors and obesity 448
- Pharmacological approaches to the problem of obesity 449
  - Centrally acting appetite suppressants 449
  - Orlistat 450
  - GLP-1 receptor agonists 450
- New approaches to obesity therapy 451

## 33 The pituitary and the adrenal cortex 452

- The pituitary gland 452
  - The anterior pituitary gland 452
  - Hypothalamic hormones 453
  - Anterior pituitary hormones 454
  - Posterior pituitary gland 457
- The adrenal cortex 458
  - Glucocorticoids 459
  - Mineralocorticoids 466
- New directions in glucocorticoid therapy 466

## 34 The thyroid 469

- Synthesis, storage and secretion of thyroid hormones 469
  - Uptake of plasma iodide by the follicle cells 469
  - Oxidation of iodide and iodination of tyrosine residues 469
  - Secretion of thyroid hormone 469
- Regulation of thyroid function 469
- Actions of the thyroid hormones 471
  - Effects on metabolism 471
  - Effects on growth and development 471
  - Mechanism of action 471
- Transport and metabolism of thyroid hormones 472
- Abnormalities of thyroid function 472
  - Hyperthyroidism (thyrotoxicosis) 472
  - Simple, non-toxic goitre 473
  - Hypothyroidism 473
- Drugs used in diseases of the thyroid 473
  - Hyperthyroidism 473
  - Hypothyroidism 474

## 35 The reproductive system 476

- Introduction 476
- Endocrine control of reproduction 476

- Neurohormonal control of the female reproductive system 476
- Neurohormonal control of the male reproductive system 478
- Behavioural effects of sex hormones 478

### Drugs affecting reproductive function 478

- Oestrogens 478
- Progestogens 481
- Postmenopausal hormone replacement therapy (HRT) 481
- Androgens 482
- Anabolic steroids 483
- Anti-androgens 483
- Gonadotrophin-releasing hormone (GnRH): agonists and antagonists 483
- Gonadotrophins and analogues 484
- Drugs used for contraception 485
  - Oral contraceptives 485
  - Other drug regimens used for contraception 486
- The uterus 486
  - The motility of the uterus 486
  - Drugs that stimulate the uterus 486
  - Drugs that inhibit uterine contraction 488
- Erectile dysfunction 488

## 36 Bone metabolism 491

- Introduction 491
- Bone structure and composition 491
- Bone remodelling 491
  - The action of cells and cytokines 493
  - The turnover of bone minerals 493
  - Hormones involved in bone metabolism and remodelling 493
- Disorders of bone 496
- Drugs used in bone disorders 496
  - Bisphosphonates 496
  - Oestrogens and related compounds 497
  - Parathyroid hormone and analogues 498
  - Vitamin D preparations 498
  - Biopharmaceuticals 498
  - Calcitonin 499
  - Calcium salts 499
  - Calcimimetic compounds 499

## SECTION 4 Nervous system

### 37 Chemical transmission and drug action in the central nervous system 501

- Introduction 501
- Chemical signalling in the nervous system 501
- Targets for drug action 504
- Drug action in the central nervous system 504
  - Blood-brain barrier 506
- The classification of psychotropic drugs 507

### 38 Amino acid transmitters 509

- Excitatory amino acids 509
  - Excitatory amino acids as CNS transmitters 509

- Metabolism and release of excitatory amino acids 509
- Glutamate 510**
  - Glutamate receptor subtypes 510
  - Synaptic plasticity and long-term potentiation 512
  - Drugs acting on glutamate receptors 515
- $\gamma$ -aminobutyric acid 518**
  - Synthesis, storage and function 518
  - GABA receptors: structure and pharmacology 518
  - Drugs acting on GABA receptors 519
- Glycine 520**
- Concluding remarks 522**

## 39 Other transmitters and modulators 524

---

- Introduction 524**
- Noradrenaline 524**
  - Noradrenergic pathways in the CNS 524
  - Functional aspects 524
- Dopamine 526**
  - Dopaminergic pathways in the CNS 526
  - Dopamine receptors 527
  - Functional aspects 527
- 5-Hydroxytryptamine 529**
  - 5-HT pathways in the CNS 529
  - 5-HT receptors in the CNS 529
  - Functional aspects 530
  - Clinically used drugs 531
- Acetylcholine 531**
  - Cholinergic pathways in the CNS 531
  - Acetylcholine receptors 531
  - Functional aspects 532
- Purines 533**
- Histamine 534**
- Other CNS mediators 534**
  - Melatonin 534
  - Nitric oxide 535
  - Lipid mediators 535
- A final message 537**

## 40 Neurodegenerative diseases 539

---

- Protein misfolding and aggregation in chronic neurodegenerative diseases 539**
- Mechanisms of neuronal death 540**
  - Excitotoxicity 541
  - Apoptosis 541
  - Oxidative stress 543
- Ischaemic brain damage 543**
  - Pathophysiology 544
  - Therapeutic approaches 544
- Dementia 544**
  - Pathogenesis of Alzheimer's disease 545
  - Pathogenesis of dementia with Lewy bodies 546
  - Therapeutic approaches to dementia 547
- Parkinson's disease 548**
  - Features of Parkinson's disease 548
  - Pathogenesis of Parkinson's disease 549
  - Drug treatment of Parkinson's disease 550
- Essential tremor 553**

- Huntington's disease 554
- Amyotrophic lateral sclerosis 554
- Spinal muscular atrophy 554
- Multiple sclerosis 554

## 41 General anaesthetic agents 557

---

- Introduction 557**
- Mechanism of action of anaesthetic drugs 557**
  - Lipid solubility 557
  - Effects on ion channels 558
  - Effects on the nervous system 559
  - Effects on the cardiovascular and respiratory systems 559
- Intravenous anaesthetic agents 560**
  - Propofol 560
  - Thiopental 560
  - Etomidate 561
  - Other intravenous agents 562
- Inhalation anaesthetics 563**
  - Pharmacokinetic aspects 563
- Individual inhalation anaesthetics 565**
  - Isoflurane, desflurane, sevoflurane, enflurane and halothane 566
  - Nitrous oxide 566
- Sedation and balanced anaesthesia 567**

## 42 Headache 568

---

- Headache 568**
- Types of headaches 568**
  - Migraine 568
  - Tension-type headaches 570
  - Trigeminal autonomic cephalalgias 571
  - Miscellaneous primary headaches 571
- Drug therapy for headache 571**
  - Drugs acting on the 5-HT system 571
  - Drugs acting on the CGRP system 572
  - Anti-inflammatory drugs 573
  - Centrally acting drugs 573
  - Cardiovascular drugs 573
  - Miscellaneous group 574
  - Other non-pharmacological treatments 574
- Summary 574**

## 43 Analgesic drugs 575

---

- Introduction 575**
- Neural mechanisms of pain 575**
  - Modulation in the nociceptive pathway 576
  - Chemical signalling in the nociceptive pathway 579
- Analgesic drugs 581**
  - Opioid drugs 581
  - Paracetamol 590
- Chronic pain 591**
  - Treatment of chronic secondary pain 591
  - Treatment of chronic primary pain 592
  - Other drugs used to treat pain 592

## 44 Local anaesthetics and other drugs affecting sodium channels 595

---

- Local anaesthetics 595**

## SECTION 5 Drugs used for the treatment of infections and cancer

### 51 Basic principles of antimicrobial chemotherapy 690

Background 690

The molecular basis of chemotherapy 690

Bacteria 690

Biochemical reactions as potential targets 691

The formed structures of the cell as potential targets 696

Resistance to antibacterial drugs 697

The spread of antibiotic resistance 698

Biochemical mechanisms of resistance to antibiotics 700

Current status of antibiotic resistance in bacteria 701

Resistance to other antimicrobials 702

### 52 Antibacterial drugs 704

Introduction 704

Gram staining and its significance for drug action 704

Antibacterial agents that interfere with folate synthesis or action 704

Sulfonamides 704

Trimethoprim 706

$\beta$ -lactam antibiotics and other agents that interfere with bacterial wall or membrane synthesis 707

Penicillins 707

Cephalosporins and cephamycins 709

Other  $\beta$ -lactam antibiotics 710

Other antibiotics that inhibit bacterial cell wall peptidoglycan synthesis 710

Antimicrobial agents affecting bacterial protein synthesis 711

Tetracyclines 711

Aminoglycosides 713

Macrolides 713

Oxazolidinones 714

Fusidic acid 714

Streptogramins 714

Clindamycin 714

Antimicrobial agents affecting topoisomerase 715

Quinolones 715

Miscellaneous antibacterial agents 716

Antimycobacterial agents 716

Drugs used to treat tuberculosis 716

Drugs used to treat leprosy 718

Prospects for new antibacterial drugs 719

### 53 Antiviral drugs 721

Background information about viruses 721

An outline of virus structure 721

The lifecycle of viruses 721

Mechanisms of viral replication 722

The host-virus interaction 723

Host defences against viruses 723

Viral ploys to circumvent host defences 724

HIV and AIDS 725

Induction of the disease 725

Progress of infection 725

COVID-19 728

Antiviral drugs 729

DNA polymerase inhibitors 729

Reverse transcriptase inhibitors 730

Non-nucleoside reverse transcriptase inhibitors 731

Protease inhibitors 731

Neuraminidase inhibitors and inhibitors of viral coat disassembly 732

Drugs acting through other mechanisms 732

Biopharmaceutical antiviral drugs 732

Other agents 733

Combination therapy for HIV 733

COVID-19 pharmacotherapy 734

Prospects for new antiviral drugs 735

### 54 Antifungal drugs 736

Fungi and fungal infections 736

Drugs used to treat fungal infections 737

Antifungal antibiotics 737

Synthetic antifungal drugs 739

Future developments 740

### 55 Antiprotozoal drugs 742

Background 742

Host-parasite interactions 742

Malaria and antimalarial drugs 742

The life cycle of the malaria parasite 744

Antimalarial drugs 745

Potential new antimalarial drugs 751

Amoebiasis and amoebicidal drugs 752

Trypanosomiasis and trypanocidal drugs 753

Other protozoal infections and drugs used to treat them 754

Leishmaniasis 754

Trichomoniasis 754

Giardiasis 755

Toxoplasmosis 755

Pneumocystis 755

Future developments 755

### 56 Anthelmintic drugs 757

Helminth infections 757

Anthelmintic drugs 758

Benzimidazoles 760

Praziquantel 761

Piperazine 761

Diethylcarbamazine 761

Niclosamide 761

Levamisole 762

Ivermectin 762

Resistance to anthelmintic drugs 762

Vaccines and other novel approaches 763

### 57 Anticancer drugs 764

Introduction 764

The pathogenesis of cancer 764



- The genesis of a cancer cell 765
- The special characteristics of cancer cells 765
- General principles of cytotoxic anticancer drugs 767**
- Anticancer drugs 768**
  - Alkylating agents and related compounds 771
  - Antimetabolites 773
  - Cytotoxic antibiotics 774
  - Plant derivatives 775
  - Hormones 776
  - Hormone antagonists 776
  - Monoclonal antibodies 777
  - Protein kinase inhibitors 778
  - Miscellaneous agents 779
  - Resistance to anticancer drugs 780
  - Combination therapies 780
  - Control of emesis and myelosuppression 781
- Future developments 781**

**SECTION 6 Special topics**

**58 Harmful effects of drugs 783**

- Introduction 783**
- Classification of adverse drug reactions 783**
  - Adverse effects related to the known pharmacological action of the drug 784
  - Adverse effects unrelated to the known pharmacological action of the drug 784
- Drug toxicity 784**
  - Toxicity testing 784
  - General mechanisms of toxin-induced cell damage and cell death 785
  - Mutagenesis and assessment of genotoxic potential 787

**47 Antipsychotic drugs 626**

**57 Anticancer drugs 764**

- Immunological reactions to drugs 791**
  - Immunological mechanisms 791
  - Clinical types of allergic response to drugs 791

**59 Lifestyle and drugs in sport 794**

- What are lifestyle drugs? 794**
- Classification of lifestyle drugs 794**
- Cognitive enhancers 795**
- Drugs and sex 796**
- Drugs in sport 797**
  - Anabolic steroids and related compounds 798
  - Drugs that increase oxygen delivery to muscles 799
- Regulatory, societal and ethical issues 800**
- Conclusion 801**

**60 Drug discovery and development 802**

- Drug discovery: background 802**
- The stages of a project 803**
  - The drug discovery phase 804
  - Preclinical development 806
  - Clinical development 807
- Biopharmaceuticals 808**
- Commercial aspects 808**
  - Drug repurposing 809
  - Generic drugs 809
- Future prospects 809**
- A final word 811**

Index 812

Self-assessment questions compiled by Dr. Christine Edmead, University of Bath, are available through eBooks.Health.Elsevier.com

**50 Drug development 802**